A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer
Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
DRUG: SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab|DRUG: Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin|DRUG: Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0 （Stage I）, 2 years|BIRC-assessed progression-free survival (PFS) as per RECIST v1.1（Stage II）, 2 years
Progression free survival (PFS)（Stage I）, 2 years|Objective response rate (ORR)（Stage I）, 2 years|Disease control rate (DCR) （Stage I）, 2 years|Duration of response (DOR) （Stage I）, 2 years|Overall survival (OS) （Stage I）, 2 years|Progression free survival (PFS)（Stage II）, 2 years|Objective response rate (ORR)（Stage II）, 2 years|Disease control rate (DCR)（Stage II）, 2 years|Duration of response (DOR) （Stage II）, 2 years|Overall survival (OS) （Stage II）, 2 years|Incidence and severity of adverse events (AEs), serious adverse events （Stage II）, 2 years|(SAEs), and immune-related adverse events (irAEs) as per NCI-CTC AE 5.0（Stage II）, 2 years
Evaluate efficacy and safety of SHR-1701 in combination with bevacizumab and chemotherapy in advanced or metastatic non-squamous non-small-cell lung cancer with EGFR mutation after failure of TKIs